Genetic and pharmacologic studies in mice support this framework, although receptor specificity and downstream signaling remain areas of active investigation
If a patient has already been on a higher dose of semaglutide, I may start tirzepatide at a slightly higher dose, as their body is already accustomed to medications in the incretin class and is therefore less likely to experience adverse effects
OHarte (University of Ulster, Coleraine, Northern Ireland, UK) for the gift of the GRAs peptides N and R
Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors
But significantly, by week 48, 93% of patients taking the higher dose lost enough liver fat to drop below 5%